Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial

AIMS/HYPOTHESIS: Type 1 diabetes results from a chronic autoimmune process continuing for years after presentation. We tested whether treatment with teplizumab (a Fc receptor non-binding anti-CD3 monoclonal antibody), after the new-onset period, affects the decline in C-peptide production in individ...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Herold, K. C., Gitelman, S. E., Willi, S. M., Gottlieb, P. A., Waldron-Lynch, F., Devine, L., Sherr, J., Rosenthal, S. M., Adi, S., Jalaludin, M. Y., Michels, A. W., Dziura, J., Bluestone, J. A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2012
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3537871/
https://ncbi.nlm.nih.gov/pubmed/23086558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-012-2753-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak